Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Europe's antibiotic resistance problem is worsening in key areas, even as overall antibiotic use dips. New reports show a 72% surge in carbapenem-resistant Klebsiella pneumoniae bloodstream infections since 2019, and France recorded a 310% rise in CRE hospital cases over the same period. Officials across Europe and Australia are urging urgent, coordinated action before treatment options run out.
Europe is making some progress on antibiotic use — but not nearly enough. New reports from the European Centre for Disease Prevention and Control (ECDC) show a 5% drop in human antibiotic consumption since 2019, a step in the right direction but well short of the EU's 2030 target of a 20% reduction. Meanwhile, the share of first-line antibiotics being used stands at 62.5%, still below the 65% goal.
The more alarming story is on the resistance front. While MRSA bloodstream infections fell 19% since 2019, carbapenem-resistant Klebsiella pneumoniae infections surged 72% — a dangerous trend given CRE's limited treatment options and high mortality risk. France reported a 310% rise in CRE hospital cases since 2019, and Australia flagged a 25.2% jump in "critical" antibiotic resistance in 2024. Officials are calling for swift action on stewardship, infection control, and genomic surveillance.
Why it matters: Antimicrobial resistance isn't a distant threat — it's already straining healthcare systems and killing tens of thousands each year. Without swift action on stewardship, infection control, and surveillance, the pipeline of effective antibiotics could run dry, leaving patients with few options for life-threatening infections.